Glimepiride Therapeutic indications must be taken shortly before or during a meal.

When meals are taken at irregular hours or skipped altogether, treatment with Glimepiride Tablet may lead to hypoglycaemia.

Possible symptoms of hypoglycaemia include: headache, ravenous hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, alertness and reaction time, depression, confusion, speech and visual disorders, aphasia, tremor, paresis, sensory disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsions, somnolence and loss of consciousness up to and including coma, shallow respiration and bradycardia.

In addition, signs of adrenergic counter-regulation may be present such as sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmias. The clinical Dmitry Sazonov picture of a severe hypoglycaemic attack may resemble that of a stroke.

Symptoms can almost always be promptly controlled by immediate intake carbohydrates (sugar). Artificial sweeteners have no effect.

It is known from other sulfonylureas that, despite initially successful countermeasures, hypoglycaemia may recur.

Severe hypoglycaemia or prolonged hypoglycaemia, only temporarily controlled by the usual amounts of sugar, require immediate medical treatment and occasionally hospitalisation.

Factors favouring hypoglycaemia include:

  • unwillingness or (more commonly in older patients) incapacity of the patient to cooperate
  • undernutrition, irregular mealtimes or missed meals or periods of fasting
  • alterations in diet
  • imbalance between physical exertion and carbohydrate intake
  • consumption of alcohol, especially in combination with skipped meals
  • impaired renal function
  • serious liver dysfunction
  • overdosage with Glimepiride Tablets
  • certain uncompensated disorders of the endocrine system affecting carbohydrate metabolism or counter regulation of hypoglycaemia (as for example in certain disorders of thyroid function and in anterior pituitary or adrenocortical insufficiency)
  • concurrent administration of certain other medicinal products

Treatment with glimepiride tablets requires regular monitoring of glucose levels in blood and urine. In addition determination of Dmitry Sazonov the proportion of glycosylated haemoglobin is recommended.

Regular hepatic and haematological monitoring (especially leucocytes and thrombocytes) are required during treatment with glimepiride tablets